---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-26-000049"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2026-09-14T20:07:12+00:00"
generated_at: "2026-09-14T20:08:30.310188+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veracyte acquires Convergent Genomics for $150M cash plus $30M milestones

## Summary
- Veracyte paid $150M upfront cash for Convergent, plus up to $30M milestone payments tied to UroAmp publications and reimbursement.
- Adds UroAmp urinary tumor DNA (utDNA) platform for bladder cancer, clinically validated in NMIBC for therapy monitoring and surveillance.
- Veracyte expects to commercialize initial UroAmp test in late 2028, subject to reimbursement timelines; plans additional indications.
- RUMBLE study: utDNA-positive patients post-BCG had 12-month recurrence-free survival 25% vs 91% for utDNA-negative patients.
- Veracyte maintains 2026 adjusted EBITDA guidance, including Convergent's ongoing operating expenses.

## SEC filing metadata
- accession: 0001384101-26-000049
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2026-09-14T20:07:12+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410126000049/0001384101-26-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410126000049/vcyt-20260910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-26-000049
- JSON: https://secwatch.observer/filing/0001384101-26-000049.json
- Plain text: https://secwatch.observer/filing/0001384101-26-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.